26278-83-1
26278-83-1
Chemical Structure
PGL-135
- CAS No.: 26278-83-1
- Formula:C9H10N2OS
- Molecular Weight:194.25
IUPAC Name: 2-amino-4,7-dimethylbenzo[d]thiazol-6-ol
InChIKey: RUTNKAMSWIPHJW-UHFFFAOYSA-N
SMILES: OC1=CC(=C2N=C(SC2=C1C)N)C
Biological Activity: PGL-135 is a blood-brain barrier-permeable Huntingtin aggregation inhibitor. PGL-135 is applicable to research related to Huntington's disease[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
PGL-135 | PGL-135 is a blood-brain barrier-permeable Huntingtin aggregation inhibitor. PGL-135 is applicable to research related to Huntington's disease. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Hockly E, et al. Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease. Neurobiology of disease. 2006 Jan;21(1):228-36.
- [2]. Ahamad S, et al. The Emerging Landscape of Small-Molecule Therapeutics for the Treatment of Huntington's Disease. J Med Chem. 2022 Dec 22;65(24):15993-16032.
- [3]. Heiser V, et al. Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay. Proceedings of the National Academy of Sciences of the United States of America. 2002 Dec 10;99 Suppl 4(Suppl 4):16400-6.
- [4]. Takahashi T, et al. Soluble polyglutamine oligomers formed prior to inclusion body formation are cytotoxic. Hum Mol Genet. 2008 Feb 1;17(3):345-56.
